Tom Piotrowski speaks with Bionomics (BNO) CEO & Managing Director, Deborah Rathjen about clinical trial results of its anxiety drug BNC210 and its Phase 2 trial for managing Post Traumatic Stress Disorder (PTSD) To view more Executive Series interviews, visit: (VIEW LINK)